Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
You may also be interested in...
FDA wants another Phase III trial with non-Hodgkins lymphoma drug.
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.